As of June 9, 2025, Autek China Inc (300595.SZ) reports a Gross Margin of 73.24%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Autek China Inc's Gross Margin
Over recent years, Autek China Inc's Gross Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2024-12-31 | 73.24% |
| 2023-12-31 | 74.67% |
| 2022-12-31 | 76.89% |
| 2021-12-31 | 76.69% |
| 2020-12-31 | 78.55% |
This slight upward trend highlights how Autek China Inc manages its operational efficiency and pricing power over time.
Comparing Autek China Inc's Gross Margin to Peers
To better understand Autek China Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Autek China Inc (300595.SZ) | 73.24% |
| Sansure Biotech Inc (688289.SS) | 81.00% |
| Jafron Biomedical Co Ltd (300529.SZ) | 80.57% |
| Kangji Medical Holdings Ltd (9997.HK) | 79.08% |
| Shanghai MicroPort Endovascular MedTech Group Co Ltd (688016.SS) | 72.62% |
| Eyebright Medical Technology Beijing Co Ltd (688050.SS) | 65.97% |
Compared to its competitors, Autek China Inc's Gross Margin is among the highest compared to peers, indicating superior product pricing power or cost efficiency in production.